These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16878798)

  • 1. [Cost and quality aspects in the treatment of Parkinson's disease].
    Müller T; Dodel R; Fritze J
    Z Arztl Fortbild Qualitatssich; 2006; 100(4):291-5. PubMed ID: 16878798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
    Hjelmgren J; Ghatnekar O; Reimer J; Grabowski M; Lindvall O; Persson U; Hagell P
    Parkinsonism Relat Disord; 2006 Oct; 12(7):443-52. PubMed ID: 16798054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
    Chen JJ
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic analysis of spa therapy in Parkinson's disease.
    Brefel-Courbon C; Desboeuf K; Thalamas C; Galitzky M; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 2003 May; 18(5):578-84. PubMed ID: 12722173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.
    Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU
    J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of Parkinson's disease.
    Shan DE; Wu HC; Chan LY; Liu KD
    Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease.
    Martinez-Martin P; Deuschl G
    Mov Disord; 2007 Apr; 22(6):757-65. PubMed ID: 17343275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reoperation for suboptimal outcomes after deep brain stimulation surgery.
    Ellis TM; Foote KD; Fernandez HH; Sudhyadhom A; Rodriguez RL; Zeilman P; Jacobson CE; Okun MS
    Neurosurgery; 2008 Oct; 63(4):754-60; discussion 760-1. PubMed ID: 18981887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.
    Müller T; Voss B; Hellwig K; Przuntek H
    NeuroRehabilitation; 2003; 18(3):271-5. PubMed ID: 14530592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct medical costs associated with Parkinson's disease: a population-based study.
    Leibson CL; Long KH; Maraganore DM; Bower JH; Ransom JE; O'Brien PC; Rocca WA
    Mov Disord; 2006 Nov; 21(11):1864-71. PubMed ID: 16977632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.